Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events
- 1 February 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (681), eabq5241
- https://doi.org/10.1126/scitranslmed.abq5241
Abstract
In October 2019, Novartis launched brolucizumab, a single-chain variable fragment molecule targeting vascular endothelial growth factor A, for the treatment of neovascular age-related macular degeneration. In 2020, rare cases of retinal vasculitis and/or retinal vascular occlusion (RV/RO) were reported, often during the first few months after treatment initiation, consistent with a possible immunologic pathobiology. This finding was inconsistent with preclinical studies in cynomolgus monkeys that demonstrated no drug-related intraocular inflammation, or RV/RO, despite the presence of preexisting and treatment-emergent antidrug antibodies (ADAs) in some animals. In this study, the immune response against brolucizumab in humans was assessed using samples from clinical trials and clinical practice. In the brolucizumab-naïve population, anti-brolucizumab ADA responses were detected before any treatment, which was supported by the finding that healthy donors can harbor brolucizumab-specific B cells. This suggested prior exposure of the immune system to proteins with structural similarity. Experiments on samples showed that naïve and brolucizumab-treated ADA-positive patients developed a class-switched, high-affinity immune response, with several linear epitopes being recognized by ADAs. Only patients with RV/RO showed a meaningful T cell response upon recall with brolucizumab. Further studies in cynomolgus monkeys preimmunized against brolucizumab with adjuvant followed by intravitreal brolucizumab challenge demonstrated that high ADA titers were required to generate ocular inflammation and vasculitis/vascular thrombosis, comparable to RV/RO in humans. Immunogenicity therefore seems to be a prerequisite to develop RV/RO. However, because only 2.1% of patients with ADA develop RV/RO, additional factors must play a role in the development of RV/RO.Keywords
This publication has 22 references indexed in Scilit:
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular DegenerationOphthalmology, 2020
- Human Memory B Cells Harbor Diverse Cross-Neutralizing Antibodies against BK and JC PolyomavirusesImmunity, 2019
- Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal BiologicsJournal of Ocular Pharmacology and Therapeutics, 2018
- Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeuticsRegulatory Toxicology and Pharmacology, 2017
- Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune ComplexesToxicologic Pathology, 2014
- T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigationClinical Immunology, 2013
- Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1Journal of Clinical Immunology, 2013
- Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathwaysBlood, 2011
- Cleavage of IgGs by proteases associated with invasive diseasesmAbs, 2010
- Signs and Symptoms of Uveitis*American Journal of Ophthalmology, 1959